Swiss Pharmaceutical Company Roche Holding Ltd. and biotech drug maker Trimeris Inc. announced the potential benefits of their HIV drug Fuzeon along with Merck & Co.'s drug MK-0518, still undergoing clinical trials, is capable of cutting the levels of the virus to incredible levels, in a majority of study subjects.
A study to test the efficacy of the drug, sponsored by Merck, found that 90 percent to 95 percent of a section of patients who were administered Fuzeon for the first time along with MK-0518, showed incredible reduction in HIV, as against the 60 percent to 70 percent of the section who were administered MK-0518 alone.
Roche and Trimeris are ecstatic with the path breaking success rates, evident during clinical trials of HIV patients who have been suffering the drug-resistant virus. Following this announcement, shares of Trimeris showed a heady jump to 83 cents on NASDAQ. Shares of Merck plummeted 18 cents to $41.76 on the New York Stock Exchange.